Physician profile
Kim Thomas
NPI 1033184163
$551.97
in general payments reported to CMS, 2019-2025
15 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.80 · 2022: $67.46 · 2023: $265 · 2024: $155 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $119.83 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Edwards Lifesciences Corporation | $97.22 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.87 | 2023-2024 | Jardiance |
| Atricure, INC. | $43.75 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $31.23 | 2023-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.46 | 2021-2025 | Lifevest |
| Amgen INC. | $27.90 | 2023 | Repatha |
| Lantheus Medical Imaging, INC. | $25.89 | 2024 | |
| Abbott Laboratories | $24.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.26 | 2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $19.11 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.91 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $17.62 | 2024 | Nexletol |
| Sobi, INC | $15.88 | 2025 | |
| Philips North America LLC | $13.26 | 2024 | (Cm9) Amb Mon & Diag Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.